Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

Abstract Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gaia Griguolo, Maria Vittoria Dieci, Laia Paré, Federica Miglietta, Daniele Giulio Generali, Antonio Frassoldati, Luigi Cavanna, Giancarlo Bisagni, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Guido Ficarra, Aleix Prat, Pierfranco Conte, Valentina Guarneri
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/3153978b88de488eab2304b48b93ed3a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.

Ejemplares similares